Canine parvovirus type 2 (CPV-2) is the etiological agent of an epizootic severe gastroenteritis of dogs \[[@r2], [@r10], [@r38]\]. It has genomic substitution rates similar to those of RNA viruses, with values of about 10^−4^ substitutions per site per year, and host-immunity pressure may contribute to the progressive emergence of CPV-2 antigenic variants \[[@r34]\]. During 1979--1981, an antigenic variant, CPV-2a, was found. In 1984, a second variant, CPV-2b, was identified \[[@r23], [@r27], [@r28]\]. These antigenic types differ from the original CPV-2 in the VP2 gene, with five distinct amino acid differences that are mostly in the VP2 domain interacting with the host-cell transferrin receptor (TfR) \[[@r4], [@r8], [@r29]\]. During the last few decades, CPV-2a/2b with the Ser297Ala mutation was designated as new CPV-2a/2b \[[@r11], [@r23], [@r26]\]. Currently, new CPV-2a and new CPV-2b appear to have replaced the prototype CPV-2a and CPV-2b and to have become the predominant types, and they appear to be co-circulating in many countries \[[@r13], [@r16], [@r24], [@r26], [@r40], [@r41]\]. Another antigenic variant having an amino acid substitution (Asp426Glu), named as CPV-2c, was first reported in Italy in 2000 \[[@r6]\], and it is the most predominant variant in Italy, Germany, Uruguay and Argentina currently \[[@r10],[@r11],[@r12], [@r25], [@r39]\]. CPV-2 is considered the main pathogen responsible for acute gastroenteritis in dogs. However, CPV variants can also infect feline hosts \[[@r5], [@r35]\]. In Germany, CPV was previously detected in only approximately 10% of feline samples \[[@r37]\], but in Vietnam and Taiwan, reports estimated that up to approximately 80% of diseased cats were infected with CPV \[[@r19]\]. Some reports previously found that new-type CPV-2a and CPV-2b have been the predominant types in some provinces of China since the 1990s \[[@r42]\], while the epidemic situation of CPV variants in the domestic cat in mainland of China is still unknown.

In the present study, to clarify the evolution of CPV-2, which has recently been considered to be epidemic in China, and compare the epidemic isolates with the vaccine strain, the VP2 gene sequences of CPV-2 detected in Beijing from 2010 to 2013 were analyzed and compared with strains from China, Korea and other areas throughout the world. A total of 352 samples (blood, feces and secretions) from domestic dogs and domestic cats with diarrhea or bloody diarrhea were collected during 2010--2013, and subjected PCR. The primers used for PCR are shown in [Table 1](#tbl_001){ref-type="table"}Table 1.The primers used for PCR detection of CPVPrimerSequence (5′→3′)Positions\
(in VP2 gene)Fragment lengthCPV-1F CPV-1RTTAAAGACTGTTTCAGAATCTGC AATCTCTCAGGTGTTTCTCCTGTT448--470 1170--1193746 bpCPV-2F CPV-2RGGCGAATTCATGAGTGATGGAGCAGTTC CGCCTCGAGATATAATTTTCTAGGTGCT1--19 1733--17521,752 bp. A 1752 bp fragment covering the full-length sequence of the VP2 gene was successfully amplified from 55 samples (15.63%); among them, BJ-E13-2012 and BJ-E53-2012 collected from cats were identified as new CPV-2a (12.5%) and showed nucleotide identities of 100% with CPV strains collected from domestic dogs, but their infectiousness and pathogenicity in cats and dogs still need a further study. The sequences were submitted to GenBank. The GenBank accession numbers are KF803589 to KF803643. Detailed information on the origin and accession numbers of the CPV-positive samples is shown in [Table 2](#tbl_002){ref-type="table"}Table 2.Detailed informations of the CPV-positive samplesStrainsGenBank IDSampling yearHostAgeClinical signsSample sourceVaccinatedGenetypeBJ-A1KF8035892010Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-A2KF8035902010Domestic dog2 monthsVomit and diarrheaBloodNot completelyNew CPV-2a likeBJ-A45KF8035912010Domestic dog3 monthsCough and diarrheaFecesNot completelyCPV-2aBJ-A48KF8035922010Domestic dog10 monthsCough and diarrheaSecretionsNot completelyNew CPV-2aBJ-A49KF8035932010Domestic dog18 monthsRecovery phaseFecesYesNew CPV-2aBJ-A50KF8035942010Domestic dog2 monthsRecovery phaseFecesNot completelyNew CPV-2a likeBJ-A53KF8035952010Domestic dog2 monthsRecovery phaseFecesYesNew CPV-2aBJ-A57KF8035962010Domestic dog2 monthsRestored from diarrheaFecesYesNew CPV-2aBJ-A61KF8035972010Domestic dog4 monthsRestored from diarrheaFecesNot completelyNew CPV-2aBJ-A63KF8035982010Domestic dog4 monthsRestored from diarrheaFecesYesNew CPV-2bBJ-A64KF8035992010Domestic dog6 monthsInjuryFecesNot completelyNew CPV-2aBJ-A68KF8036002010Domestic dog6 monthsInjuryBloodYesNew CPV-2a likeBJ-A69KF8036012010Domestic dog6 monthsDiarrheaFecesYesNew CPV-2a likeBJ-A72KF8036022010Domestic dog7 monthsRestored from diarrheaFecesNot completelyNew CPV-2aBJ-A108KF8036032010Domestic dog2 monthsDiarrhea and anorexiaFecesNot completelyNew CPV-2bBJ-B4KF8036042011Domestic dog3 monthsDiarrheaFecesNot completelyNew CPV-2aBJ-B5KF8036052011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B6KF8036062011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2bBJ-B8KF8036072011Domestic dog2 monthsVomitFecesNot completelyNew CPV-2aBJ-B10KF8036082011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B11KF8036092011Domestic dog2 monthsVomit and diarrheaFecesYesNew CPV-2aBJ-B13KF8036102011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B16KF8036112011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2bBJ-B19KF8036122011Domestic dog12 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B21KF8036132011Domestic dog3 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B22KF8036142011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B25KF8036152011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B26KF8036162011Domestic dog2 monthsCough and diarrheaSecretionsNot completelyNew CPV-2aBJ-B28KF8036172011Domestic dog3 monthsDiarrheaFecesNot completelyNew CPV-2aBJ-B31KF8036182011Domestic dog4 monthsVomit and bloodyFecesNot completelyNew CPV-2aBJ-B32KF8036192011Domestic dog12 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B33KF8036202011Domestic dog2 monthsDiarrhea and bloodyFecesYesNew CPV-2aBJ-B34KF8036212011Domestic dog3 monthsVomit and bloodyFecesNot completelyNew CPV-2aBJ-B38KF8036222011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B39KF8036232011Domestic dog3 monthsAnorexiaFecesNot completelyNew CPV-2aBJ-B40KF8036242011Domestic dog10 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-B41KF8036252011Domestic dog3 monthsVomit and diarrheaFecesYesNew CPV-2aBJ-B42KF8036262011Domestic dog4 monthsVomit and diarrheaFecesYesNew CPV-2aBJ-B43KF8036272011Domestic dog3 monthsVomitFecesNot completelyNew CPV-2bBJ-B44KF8036282011Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-D4KF8036292012Domestic dog2 monthsDiarrheaFecesNot completelyNew CPV-2aBJ-D6KF8036302012Domestic dog2 monthsVomit and diarrheaFecesYesNew CPV-2aBJ-D14KF8036312012Domestic dog1 monthCoughFecesNot completelyNew CPV-2aBJ-D15KF8036322012Domestic dog2 monthsAnorexia and VomitFecesNot completelyNew CPV-2aBJ-E4KF8036332012Domestic dog2 yearsAnorexia and diarrheaFecesNot completelyNew CPV-2aBJ-E13KF8036342012Domestic cat6 monthsHealthBloodNot completelyNew CPV-2aBJ-E14KF8036352012Domestic dog5 yearsHealthBloodYesNew CPV-2aBJ-E34KF8036362012Domestic dog2 monthsAnorexia and diarrheaFecesNot completelyNew CPV-2aBJ-E53KF8036372012Domestic cat7 monthsDiarrheaBloodNot completelyNew CPV-2aBJ-E64KF8036382012Domestic dog3 monthsVomitFecesNot completelyNew CPV-2aBJ-E81KF8036392012Domestic dog7 monthsDiarrheaFecesNot completelyNew CPV-2aBJ-P21KF8036402013Domestic dog2 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-P27KF8036412013Domestic dog7 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-P33KF8036422013Domestic dog3 monthsVomit and diarrheaFecesNot completelyNew CPV-2aBJ-P34KF8036432013Domestic dog4 monthsVomit and diarrheaFecesNot completelyNew CPV-2aTable 3. Table of statistics of mutation sites, types and rates in VP2 genesaa sites87101139187188192202219267297300305308324347375386426440555aa mutationL→MT→IV→IP→I\
P→QA→QS→FP→TI→KF→YS→AA→GD→YV→IY→IA→TD→NQ→KN→DT→AI→VSample numbers564211112454545525111141755Mutation rates (%)9.0910.917.273.641.821.821.821.8243.6498.1898.181003.6482.731.841.841.847.2730.91100. The resulting sequences were aligned with CPV reference isolates retrieved from the GenBank database. Sequences comparisons showed no deletion or shift in any sequences of the detected samples, and the nucleotide identities and deduced aa sequences identities were 98.2--100% and 97.7--100%, respectively, when compared with the CPV reference isolates.

Mutations in the VP2 protein are associated with the CPV genotypes, so the nucleotide sequences were translated into aa sequences. All samples, except one original CPV2a (BJ-A45-2010), were identified as "new CPV-2a/2b" reported worldwide and were identified as "new CPV-2a/2b" \[[@r9], [@r20], [@r22]\]. Previous research has shown residue 297 is under strong positive selection \[[@r30], [@r35]\]. Also, the 297Ala variant can not be distinguished serologically and does not change the viral antigenic type, but it potentially has a marked influence on host adaptation. Only four samples (BJ-A63-2010, BJ-B6-2011, BJ-B16-2011 and BJ-B43-2011) with Asn426Asp and ser297Ala mutations were characterized as new CPV-2b (7.27%). New CPV-2a accounted for 90.9%, while no CPV-2c was detected. Five samples (BJ-A2-2010, BJ-A49-2010, BJ-A68-2010, BJ-A69-2010 and BJ-A108-2010) also present Met at 87 position (9.09%), and six samples (BJ-A2-2010, BJ-A45-2010, BJ-A50-2010, BJ-A68-2010, BJ-A69-2010 and BJ-A108-2010) present Ile at 101 position (10.91%), which characterized as new CPV-2a like. Four samples presented Val139Ile mutation (7.27%). There are 24 samples presented Phe267Tyr mutation (43.64%). The Phe267Tyr change also has been described in Asiatic CPV-2b from Vietnam \[[@r25]\] and in CPV-2a from Thailand \[[@r32]\] and China \[[@r31], [@r35]\]. Residue 267 is not exposed on the capsid surface \[[@r1]\], so substitutions in this position may not affect the antigenicity of the virus. Fifty four samples presented Ala300Gly mutation (98.18%). Tyr324Ile mutation was first detected in China and Korea in 2004 \[[@r20], [@r35]\], and reported among the CPV 2a/2b isolates in China \[[@r17], [@r35]\]. Previous studies have shown that residue 324 is subject to strong positive selection in all parvoviruses of carnivores \[[@r17]\]. Residue 324 is likely to have had an effect on the parvovirus host range \[[@r35]\]. It is adjacent to residue 323, and together with residue 93, affects TfR binding \[[@r18]\]. In this study, fifty one samples presented Tyr324Ile mutation (92.73%) indicated that strain with mutation Tyr324Ile is the major epidemic strain. Thr440Ala has been described in CPV-2a and CPV-2b strains from China, Korea, India, Italy, Brazil and Uruguayan \[[@r3], [@r22], [@r30], [@r31]\] and in CPV-2c strains from the United States \[[@r21]\] and Argentina \[[@r7]\]. The 440 residue is important, because it is located at the top of the three-fold spike, the main antigenic site of the virus \[[@r36]\]. This residue is undergoing positive selection and has evolved in different populations independently, which explains its world-wide presence in unrelated CPV-2 populations \[[@r12]\]. In this study, seventeen samples presented Thr440Ala mutation, which accounted for 30.91%. And, all samples presented Tyr at 305 position and Val at 555 position. Also, Ser192Phe mutation in BJ-A2-2010 was just previously reported in SC02-2011. Asp375Asn mutation in BJ-A45-2010 was just previously reported in CPV-b, GZ0201 and JL0201. Previous report has indicated that residue 375 is associated with the ability of CPV to hemagglutinate or alter pH dependence of hemagglutination \[[@r15], [@r36]\], so BJ-A45-2010 may have different coagulation feature with others. While the mutations, Pro202Thr, Ile219Vla, Ala347Thr, Gln386Lys, Pro187Gln, Ser188 Gln and Val308Ile, present in this study were interesting, because it has not been detected previously in any other strains. Pro202Thr mutation was firstly reported in BJ-A2-2010, and Ile219Vla, Ala347Thr and Gln386Lys mutations were firstly reported in BJ-A45-2010. Pro187Gln and Ser188 Gln mutations were firstly reported in BJ-A69-2010. Also, Val308Ile mutation was firstly reported in BJ-D6-2012 and BJ-D14-2012. While, Asp427His, The445Asn and Pro512His which appeared in Nanjing strains of 2009--2012 \[[@r41]\] and Thr442Ala and Gln370Arg reported in the giant panda strain B11 \[[@r15]\] were not present in this study. The detail mutation sites, types and rates in VP2 genes were shown in [Table 3](#tbl_003){ref-type="table"}. The affects of these mutations to virus itself, which appeared in this study, need our further research.

Twelve strains were detected in dogs completely immunized with CPV-2 vaccine ([Table 2](#tbl_002){ref-type="table"}). Although the effectiveness of CPV-2 vaccine against CPV-2a type has not been evaluated in China, our results showed that 12 out of 55 samples were detected as "new CPV-2a/2b" in dogs completely immunized with CPV-2 vaccine, which suggested that complete immunity may not be provided to dogs even if CPV-2 vaccines are used as previously reported \[[@r14], [@r15], [@r33], [@r35]\].

To examine the phylogenetic relationships of the 55 samples with the reference isolates, a phylogenetic tree based on the nucleotide sequence from 1 to 1752 nt of the VP2 gene was built. As shown in [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Phylogenies of the VP2 gene sequences. The phylogenetic analyses were performed using the MEGA software, version 4.0 (http://www.megasoftware.net/). The neighbor-joining method was chosen to draw the nucleotide phylogenetic tree. The reliability of the phylogenetic tree obtained for the VP2 region was evaluated by running 1,000 replicates in the bootstrap test., all the samples clustered in CPV group, while separated from FPV-b. Most of them are with the closest relationship with the Chinese isolates, such as Guanzhou (JX66-690, SC02-2011), Beijing (HQ883267, Beijing; HQ883273, BJ-2010), Wuhan (FJ432717, 08-5-WH), Nanjing (EU095252, NJ-04) and so on. All sequences are with the distant relationship with Brazil, France, Japan, Vietnam, the United States and Italy isolates. However, BJ-B25-2011, BJ-B26-2011, BJ-A72-2010 and BJ-A63-2010 are with the distant relationship with others. Interestingly, BJ-A72-2010 is with the closest relationship with vaccine strains (EU914139, Pfizer vaccine 06 GQ169553, Vac 2), CPV-2 representative strain (M38245, CPV-b) and FPV representative strain (M24004, FPV-b). BJ-A63-2010 is with the closest relationship with South Korea strain (EF599097, DH326), Taiwan strain (AY869724, Taichung) and Chinese CPV 2c strain (GU380305 08-09). As the phylogenetic tree shows, most of the viruses isolated in China formed a large cluster and certain mutations detected in Chinese CPVs probably arose during the process of local adaptation, as indicated by previous surveys \[[@r15], [@r30]\].

In summary, new CPV-2a is the prominent type of CPV in Beijing from 2010 to 2013. Few samples still present Met at 87 position, Ile at 101 position and Ala at 300 position. Most samples contained the mutation Phe267Tyr, Ala300Gly, Tyr324Ile and Thr440Ala. All samples presented Tyr at 305 position and Val at 555 position. While, Pro187Gln, Ser188 Gln, Ile219Vla, Ala347Thr, Gln386Lys and Val308Ile mutations were firstly reported in present study. Also, new CPV-2a was detected in cats with diarrhea, and CPV-2 vaccines may not provide complete immunity to dogs in China. Due to the continuing evolution of CPV, monitoring the prominent type of CPV, and detecting genetic mutation and antigenic changes, will be necessary to find new vaccines and control CPV infection in China.
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